<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01630655</url>
  </required_header>
  <id_info>
    <org_study_id>426-09</org_study_id>
    <nct_id>NCT01630655</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of Torrent Pharmaceuticals Ltd's Felodipine Extended-Release Tablets Under Fasting Condition</brief_title>
  <official_title>An Open Label, Randomised, 2-period, 2-treatment, 2-sequence, Cross-over, Single-dose Bioequivalence Study of Felodipine Extended-Release Tablets USP 10 mg (Test, Torrent Pharmaceuticals Ltd., India) Versus Felodipine Extended-Release Tablets USP 10 mg (Reference, Mylan Pharmaceuticals Inc., USA) in Healthy Human Volunteers Under Fasting Condition</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Torrent Pharmaceuticals Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Torrent Pharmaceuticals Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objective:

      Primary objective of the present study was to compare the single dose bioavailability of
      Torrent's Felodipine Extended-Release Tablets USP 10 mg and Innovator's (Mylan
      Pharmaceuticals Inc., USA) Felodipine Extended-Release Tablets USP 10 mg. Dosing periods were
      separated by a washout period of 17 days during fasting study.

      Study Design:

      Open-Label, Randomised, two Period, two treatment, Crossover, Single-Dose Bioequivalence
      Study
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <primary_outcome>
    <measure>bioequivalence based on Composite of Pharmacokinetics</measure>
    <description>bioequivalence; 90% geometric confidence interval of the ratio of least-squares means of the test to reference product should be within 80.00% - 125.00% for AUC-unf, AUCo-t and Cmax.</description>
  </primary_outcome>
  <condition>Healthy</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Torrent's Felodipine Extended-Release Tablets</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy males within the age range of 18 to 50 years.

          -  A body mass index within 18-25 Kg/m2.

          -  Given written informed consent to participate in the study.

          -  Absence of diseases markers of HIV 1 &amp; 2, Hepatitis B &amp; C virus and RPR.

          -  Absence of significant disease or clinically significant abnormal laboratory

          -  values on laboratory evaluation, medical history and physical examination during the
             screening.

          -  A normal 12-lead ECG.

          -  A normal chest X-Ray.

          -  Comprehension of the nature and purpose of the study and compliance with the
             requirements of the entire protocol.

          -  No history or no evidence of hypersensitivity or idiosyncratic reactions to other
             nitrates or nitrites.

          -  No history of allergic rash.

          -  No history of significant systemic diseases.

          -  No history of psychiatric disorders or addiction to any recreational drug or drug
             dependence.

          -  No donation of blood within 56 days prior to study check-in.

          -  No participation in any clinical study within the past 56 days.

          -  No receipt of any prescription drugs or OTC products, with in two weeks prior to study
             check-in.

          -  No history of dehydration from diarrhea, vomiting or any other reason within a period
             of 24 hours prior to study check-in.

          -  No family history of neurological disorders.

          -  Not consumed alcohol and xanthine containing food and beverages, cigarettes and
             tobacco products, for at-list 48 hours, prior to study check-in.

          -  Negative results for drugs of abuse in urine and alcohol breath analysis during
             check-in of each period.

          -  Not consumed grape fruit juice within the 48 hours prior to study check-in.

        Exclusion Criteria:

          -  Blood pressure Systolic&gt; 140 mm Hg and &lt; 110 mm Hg Diastolic&lt; 70 mm Hg &gt; 90 mm Hg

          -  History of seizures

          -  History of alcohol consumption for more than 2 units/day.

          -  High caffeine or tobacco consumption

          -  History of difficulty with donating blood or difficulty in accessibility of veins.

          -  Any unusual or abnormal diet, for whatever reason e.g. fasting due to religious
             reasons.

          -  Used any pharmacological agents known to significantly induce or inhibit drug
             metabolizing enzymes within 14 days of the start of the study
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>AXIS Clinicals Limited(formerly Trident Life Sciences Ltd.)</name>
      <address>
        <city>Miyapur</city>
        <state>Hyderabad</state>
        <zip>500 050</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 26, 2012</study_first_submitted>
  <study_first_submitted_qc>June 27, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 28, 2012</study_first_posted>
  <last_update_submitted>June 27, 2012</last_update_submitted>
  <last_update_submitted_qc>June 27, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 28, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Felodipine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

